Loading
Immunotherapy and Immune Responses / CAR-T Cell Therapy Research · Journal article
Frontiers in Oncology · August 14, 2026
A consensus or society position rather than new primary data.
This is a narrative review that surveys emerging precision immuno-oncology modalities—including ADCs, therapeutic vaccines, and adoptive cell therapies—for NSCLC treatment. It synthesizes current mechanisms and clinical progress but presents no original trial data, effect sizes, or comparative outcomes, and thus serves to orient readers to the landscape rather than to establish efficacy or practice change.
Narrative review. Non-small cell lung cancer (NSCLC) patients.
Targeted therapy and immune checkpoint inhibition have improved NSCLC treatment but remain challenged by resistance, tumor heterogeneity, and immune evasion ADCs, therapeutic cancer vaccines, and adoptive cellular therapies (CAR-T, NK cells, TILs) are described as significantly changing the systemic treatment paradigm in NSCLC Advances in neoantigen discovery, mRNA vaccine technology, and personalized vaccine design are highlighted as renewing interest in therapeutic cancer vaccines
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and researchers should view this as a comprehensive overview of emerging modalities and combination strategies rather than as evidence for a specific treatment recommendation. It provides context for evaluating individual trials and biomarker-driven patient selection in precision immuno-oncology.
A narrative review summarizing mechanisms, clinical progress, and therapeutic strategies for emerging immuno-oncology approaches in NSCLC, without original data or trial results.
As stated by the source record.
Clinicians and researchers should view this as a comprehensive overview of emerging modalities and combination strategies rather than as evidence for a specific treatment recommendation. It provides context for evaluating individual trials and biomarker-driven patient selection in precision immuno-oncology.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Targeted therapy and immune checkpoint inhibition have improved the treatment of non-small cell lung cancer (NSCLC); however, it remains one of the leading causes of cancer-related mortality worldwide. While all these therapeutic strategies have yielded clinical benefit in specific patient groups, resistance and tumor heterogeneity, short-term responses, and immune evasion remain current challenges in long-term therapeutic success. These constraints have led to the exploration of new precision immuno-oncology approaches for more specific targeting more efficient stimulation of antitumor immune responses and overcoming resistance mechanisms. Among these new modalities, antibody-drug conjugates (ADCs), therapeutic cancer vaccines, and adoptive cellular therapies are significantly changing the systemic treatment paradigm in NSCLC. Simultaneously, advances in neoantigen discovery, mRNA vaccine technology, and personalized vaccine design have renewed interest in therapeutic cancer vaccines for generating durable antitumor immune responses. In parallel, adoptive cellular immunotherapies, such as chimeric antigen receptor (CAR)-T cells, natural killer (NK)-cells, and tumor-infiltrating lymphocytes (TILs) are growing as effective approaches to improve immune-mediated tumor eradication in NSCLC. This manuscript summarizes the recent developments of these next-generation precision immuno-oncology platforms, highlighting their working mechanisms, progress in translation, and clinical use. It also explores strategies for combinational therapy, predictive biomarkers, inhibitors of tumor microenvironment modulation, and mechanisms of resistance in the context of therapeutic efficacy and patient selection. Collectively, these developing immunotherapeutic platforms as a whole constitute a brighter paradigm for more personalized and effective systemic treatment approaches in NSCLC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.